Gary Bridger
Eloxx Pharmaceuticals (United States)(US)Vertex Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Chemokine receptors and signaling, HIV Research and Treatment, Hematopoietic Stem Cell Transplantation, Immunotherapy and Immune Responses, Immune Cell Function and Interaction
Most-Cited Works
- → Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist(2005)1,093 cited
- → Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma(2009)775 cited
- → Chemokines Acting via CXCR2 and CXCR4 Control the Release of Neutrophils from the Bone Marrow and Their Return following Senescence(2003)746 cited
- → Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist(2003)716 cited
- → Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma(2009)670 cited
- → Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers